Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Few Signs Of An IPO Slowdown Despite US Biotech Stock Slump

Biotech stock valuations wavered in October with the average IPO return in the US nearing negative territory, but observers say there is still a healthy market for new biopharma offerings in 2018 and into next year.

Business Strategies Financing Outlook 2019

Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

Commercial Business Strategies Outlook 2019

Titans of Pharma 2018: An Infographic Snapshot Of The Industry's Top Leaders

In 2017, the top 15 pharma companies paid their CEOs a total of $251m in salary and other benefits, while reporting net income of $56.5bn. But while income was down 41% on 2016, compensation declined by a more modest 9%. In this infographic, Scrip provides a snapshot of these companies' leaders and the businesses they oversee.

Leadership Companies Human Capital

Why The M&A Boom Many Expected In 2018 Didn’t Happen

High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.

M & A Outlook 2019 Commercial

Back In Fashion? Boston’s CBO Talks Turkey On Reinvigorating Pharma’s Unwanted Assets

Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.

Strategy Deals Leadership

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches

CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.

Launches Sales & Earnings Neurology

Advertisement
UsernamePublicRestriction

Register

Advertisement